Preparation and characterization of polysaccharide-based nanoparticles with anticoagulant activity
Received 9 March 2012
Accepted for publication 14 April 2012
Published 18 June 2012 Volume 2012:7 Pages 2975—2986
Review by Single anonymous peer review
Peer reviewer comments 4
Luiz Cláudio da Silva,1 Thiago Garcia,1 Michela Mori,2 Giuseppina Sandri,2 Maria Cristina Bonferoni,2 Priscila V Finotelli,1 Leonardo P Cinelli,1 Carla Caramella,2 Lúcio M Cabral1
1Drug Department, Rio de Janeiro Federal University, Rio de Janeiro, Brazil; 2Department of Drug Sciences, University of Pavia, Pavia, Italy
Abstract: The aim of this study was to produce and characterize nanoparticles (NPs), combining chondroitin sulfate (CS) and fucoidan (FC) with chitosan for therapeutic purposes. These NPs were characterized by dynamic light scattering, zeta potential determination, and transmission electronic microscopy. The anticoagulant activity was determined for FC NPs and compared with FC solution at the same concentration. FC NPs showed regular shapes and better anticoagulant activity than free polysaccharide solution. FC solution did not affect coagulation compared to FC NPs, which increased up to two-fold, even at a lower concentration. Cytotoxicity and permeability tests were conducted using Caco-2 cell monolayer, exhibiting no toxic effect in this cell line and higher permeability for NP2 samples than FC solution at the same concentration.
Keywords: nanoparticles, chitosan, chondroitin sulfate, fucoidan, aPTT, Caco-2
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.